This review highlights frailty's role in guiding care to improve outcomes in patients with hematologic malignancies, suggesting better management strategies.
Frailty, distinct from chronological age, reflects physiologic reserve and predicts toxicity, treatment discontinuation, and survival across hematologic malignancies. The authors synthesize contemporary frailty tools and summarize disease-specific evidence in multiple myeloma, acute myeloid leukemia, and aggressive lymphomas. Integrating frailty measures can inform shared decision-making and guide the management of vulnerable populations to enhance therapeutic benefit and optimize quality of life.
No takes yet. Share an insight, caveat, or question.
Friend et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: